Literature DB >> 25012579

Birth Prevalence of Fatty Acid β-Oxidation Disorders in Iberia.

Hugo Rocha1, Daisy Castiñeiras, Carmen Delgado, José Egea, Raquel Yahyaoui, Yolanda González, Manuel Conde, Inmaculada González, Inmaculada Rueda, Luis Rello, Laura Vilarinho, José Cocho.   

Abstract

Mitochondrial fatty acid β-oxidation disorders (FAOD) are main targets for newborn screening (NBS) programs, which are excellent data sources for accurate estimations of disease birth prevalence. Epidemiological data is of key importance for the understanding of the natural history of the disorders as well as to define more effective public health strategies. In order to estimate FAOD birth prevalence in Iberia, the authors collected data from six NBS programs from Portugal and Spain, encompassing the screening of more than 1.6 million newborns by tandem mass spectrometry (MS/MS), and compared it with available data from other populations. The participating NBS programs are responsible for the screening of about 46% of all Iberian newborns. Data reveals that Iberia has one of the highest FAOD prevalence in Europe (1:7,914) and that Portugal has the highest birth prevalence of FAOD reported so far (1:6,351), strongly influenced by the high prevalence of medium-chain acyl-CoA dehydrogenase deficiency (MCADD; 1:8,380), one of the highest ever reported. This is justified by the fact that more than 90% of Portuguese MCADD patients are of Gypsy origin, a community characterized by a high degree of consanguinity. From the comparative analysis of various populations with comparable data other differences emerge, which points to the existence of significant variations in FAOD prevalences among different populations, but without any clear European variation pattern. Considering that FAOD are one of the justifications for MS/MS NBS, the now estimated birth prevalences stress the need to screen all Iberian newborns for this group of inherited metabolic disorders.

Entities:  

Year:  2014        PMID: 25012579      PMCID: PMC4221301          DOI: 10.1007/8904_2014_324

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  31 in total

Review 1.  Mitochondrial beta-oxidation.

Authors:  Kim Bartlett; Simon Eaton
Journal:  Eur J Biochem       Date:  2004-02

Review 2.  Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.

Authors:  Martin Lindner; Georg F Hoffmann; Dietrich Matern
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

3.  Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California.

Authors:  Natalie M Gallant; Karen Leydiker; Hao Tang; Lisa Feuchtbaum; Fred Lorey; Rebecca Puckett; Joshua L Deignan; Julie Neidich; Naghmeh Dorrani; Erica Chang; Bruce A Barshop; Stephen D Cederbaum; Jose E Abdenur; Raymond Y Wang
Journal:  Mol Genet Metab       Date:  2012-02-09       Impact factor: 4.797

4.  California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry.

Authors:  Lisa Feuchtbaum; Fred Lorey; Lisa Faulkner; John Sherwin; Robert Currier; Ajit Bhandal; George Cunningham
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

5.  The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005.

Authors:  D M Frazier; D S Millington; S E McCandless; D D Koeberl; S D Weavil; S H Chaing; J Muenzer
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

6.  Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program.

Authors:  T H Zytkovicz; E F Fitzgerald; D Marsden; C A Larson; V E Shih; D M Johnson; A W Strauss; A M Comeau; R B Eaton; G F Grady
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

7.  Screening newborns for inborn errors of metabolism by tandem mass spectrometry.

Authors:  Bridget Wilcken; Veronica Wiley; Judith Hammond; Kevin Carpenter
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

8.  Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening.

Authors:  Allan Meldgaard Lund; David Michael Hougaard; Henrik Simonsen; Brage Storstein Andresen; Mette Christensen; Morten Dunø; Kristin Skogstrand; Rikke K J Olsen; Ulrich Glümer Jensen; Arieh Cohen; Nanna Larsen; Peter Saugmann-Jensen; Niels Gregersen; Niels Jacob Brandt; Ernst Christensen; Flemming Skovby; Bent Nørgaard-Pedersen
Journal:  Mol Genet Metab       Date:  2012-06-21       Impact factor: 4.797

9.  Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England: prevalence, predictive value and test validity based on 1.5 million screened babies.

Authors:  Juliet Oerton; Javaria M Khalid; Guy Besley; R Neil Dalton; Melanie Downing; Anne Green; Mick Henderson; Steve Krywawych; James Leonard; Brage S Andresen; Carol Dezateux
Journal:  J Med Screen       Date:  2011-12-13       Impact factor: 2.136

10.  Genetic studies of the Roma (Gypsies): a review.

Authors:  L Kalaydjieva; D Gresham; F Calafell
Journal:  BMC Med Genet       Date:  2001-04-02       Impact factor: 2.103

View more
  8 in total

1.  Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities.

Authors:  Agnes Hackl; Katrin Mehler; Ingo Gottschalk; Anne Vierzig; Marcus Eydam; Jan Hauke; Bodo B Beck; Max C Liebau; Regina Ensenauer; Lutz T Weber; Sandra Habbig
Journal:  Pediatr Nephrol       Date:  2017-01-12       Impact factor: 3.714

2.  Four Years' Experience in the Diagnosis of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency in Infants Detected in Three Spanish Newborn Screening Centers.

Authors:  B Merinero; P Alcaide; E Martín-Hernández; A Morais; M T García-Silva; P Quijada-Fraile; C Pedrón-Giner; E Dulin; R Yahyaoui; J M Egea; A Belanger-Quintana; J Blasco-Alonso; M L Fernandez Ruano; B Besga; I Ferrer-López; F Leal; M Ugarte; P Ruiz-Sala; B Pérez; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2017-07-29

3.  Screening and follow-up results of fatty acid oxidative metabolism disorders in 608 818 newborns in Jining, Shandong province.

Authors:  Chiju Yang; Caihong Shi; Cheng Zhou; Qiuhua Wan; Yanbin Zhou; Xigui Chen; Xianlian Jin; Chenggang Huang; Peng Xu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

Review 4.  Acylcarnitines--old actors auditioning for new roles in metabolic physiology.

Authors:  Colin S McCoin; Trina A Knotts; Sean H Adams
Journal:  Nat Rev Endocrinol       Date:  2015-08-25       Impact factor: 43.330

Review 5.  Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders.

Authors:  Deborah Marsden; Camille L Bedrosian; Jerry Vockley
Journal:  Genet Med       Date:  2021-01-25       Impact factor: 8.822

6.  Expanded Screening of One Million Swedish Babies with R4S and CLIR for Post-Analytical Evaluation of Data.

Authors:  Lene Sörensen; Ulrika von Döbeln; Henrik Åhlman; Annika Ohlsson; Martin Engvall; Karin Naess; Carolina Backman-Johansson; Yvonne Nordqvist; Anna Wedell; Rolf H Zetterström
Journal:  Int J Neonatal Screen       Date:  2020-05-27

Review 7.  Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?

Authors:  Xiaodie Mu; Min Yang; Peiyao Ling; Aihua Wu; Hua Zhou; Jingting Jiang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-01-29       Impact factor: 3.168

8.  Admixture Has Shaped Romani Genetic Diversity in Clinically Relevant Variants.

Authors:  Neus Font-Porterias; Aaron Giménez; Annabel Carballo-Mesa; Francesc Calafell; David Comas
Journal:  Front Genet       Date:  2021-06-16       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.